Guideline Summary for Diagnosis and Treatment of Aortitis

1. Diagnostic Evaluation

• Imaging confirmation is required – CT angiography, MR angiography, or FDG‑PET should demonstrate aortic wall thickening, enhancement, edema, or stenosis/aneurysm before definitive treatment decisions are made. 1
• MR angiography with gadolinium is the preferred modality for detecting active inflammation, showing late gadolinium enhancement, T2‑weighted wall edema, and wall thickening. 1
• FDG‑PET is superior for monitoring treatment response because it identifies metabolically active inflammation via supraphysiologic FDG uptake. 1
• CT angiography provides a comprehensive anatomic map of the aorta and its branches but is limited for assessing active inflammation. 1
• Infectious aortitis must be distinguished immediately; the most common pathogens are Staphylococcus aureus and Salmonella spp., with other organisms (e.g., Treponema pallidum, Mycobacterium tuberculosis, fungi, gram‑negative bacteria) also implicated. Prompt antimicrobial therapy is mandatory. 2

2. Initial Medical Management

• Start high‑dose oral prednisone (40–60 mg/day, or 1 mg/kg up to 80 mg) immediately when aortitis is suspected, without awaiting biopsy or imaging confirmation, to prevent irreversible vascular complications. 3
• For life‑ or organ‑threatening manifestations (vision loss, stroke, myocardial or limb ischemia), give IV methylprednisolone 500–1000 mg/day for 3–5 days before transitioning to oral therapy. This pulse regimen is reserved for emergencies; it offers no advantage over oral high‑dose glucocorticoids in non‑emergent cases. 4
• Glucocorticoid monotherapy should be avoided except in mild disease or diagnostic uncertainty; combination therapy with a steroid‑sparing agent markedly reduces long‑term glucocorticoid toxicity and improves outcomes. 4

3. Steroid‑Sparing Immunosuppression

• Giant Cell Arteritis (GCA) – adjunctive therapy is indicated for refractory/relapsing disease or when glucocorticoid‑related adverse‑event risk is high. Tocilizumab (IL‑6 receptor antagonist) is preferred to lower cumulative glucocorticoid exposure and relapse rates; methotrexate is an acceptable alternative. 3
• Takayasu Arteritis – initiate a non‑glucocorticoid immunosuppressive agent at diagnosis (e.g., methotrexate 20–25 mg weekly, especially in children, or azathioprine 2 mg/kg/day). TNF inhibitors (infliximab or adalimumab) may be used when rapid disease control is required or conventional agents are contraindicated. 3
• Refractory disease after glucocorticoids plus conventional agents – add a TNF inhibitor before considering tocilizumab, based on observational data showing higher remission rates with TNF blockade. Reserve tocilizumab for cases where TNF inhibitors are unsuitable. 4

4. Antiplatelet Therapy

• The European League Against Rheumatism (EULAR) no longer recommends routine antiplatelet or anticoagulant therapy for large‑vessel vasculitis unless there is a separate indication. 3
• Low‑dose aspirin (75–150 mg daily) may be used in patients with active disease involving critical cranial, vertebrobasilar, or flow‑limiting carotid/vertebral arteries to reduce ischemic events, with caution regarding bleeding risk after surgery. 5

5. Glucocorticoid Tapering

• After achieving remission for 6–12 months, taper glucocorticoids completely rather than maintaining a low‑dose regimen. The steroid‑sparing immunosuppressive agent should be continued throughout and after the taper. 3

6. Disease Activity Monitoring

• Lifelong clinical surveillance is required because vascular remodeling can progress even when patients appear clinically quiescent. 4
• At each visit obtain four‑extremity blood pressures, perform a vascular examination for new bruits or pulse deficits, and assess constitutional (fever, weight loss, fatigue) and vascular symptoms (claudication, hypertension). 4
• Inflammatory markers (ESR, CRP) are elevated in only ~50 % of active disease episodes and must not be used in isolation; combine clinical assessment with imaging. 4
• Imaging surveillance (MRI/CT angiography or FDG‑PET) every 3–6 months during active or early disease (longer intervals once quiescent) to detect wall edema, contrast enhancement, increased thickness, or supraphysiologic FDG uptake. New arterial stenosis or wall thickening in previously unaffected territories mandates escalation of immunosuppression, even if asymptomatic. 4

7. Surgical and Interventional Considerations

• Elective revascularization (bypass, angioplasty, stenting) should be postponed until disease is quiescent, as operating during active inflammation is linked to significantly poorer outcomes. 3
• If surgery is unavoidable for life‑ or organ‑threatening ischemia, administer high‑dose glucocorticoids peri‑procedurally and ensure joint decision‑making between vascular surgeons and rheumatologists. 4
• Renovascular hypertension in Takayasu arteritis – first manage medically with antihypertensives and immunosuppression; reserve renal artery revascularization for refractory hypertension or progressive renal dysfunction despite optimized therapy. 4

8. Special Populations – Pediatric Patients

• Methotrexate is the preferred first‑line steroid‑sparing agent in children because of superior tolerability. 6
• For extensive disease crossing the diaphragm, consider cyclophosphamide induction followed by methotrexate maintenance. 6
• Alternate steroid regimens (IV pulse combined with low daily oral dosing) may improve adherence and limit growth impairment. 6

9. Common Pitfalls to Avoid

• Do not delay glucocorticoid initiation while awaiting biopsy or imaging; early treatment prevents irreversible vascular damage. 3
• Do not rely solely on inflammatory markers for disease activity assessment; they are normal in half of active cases. 4
• Do not use glucocorticoid monotherapy except for mild disease; combination therapy reduces toxicity. 4
• Do not perform elective surgery during active inflammation; outcomes are markedly worse. 4
• Do not discontinue monitoring in clinical remission; silent vascular remodeling can occur. 4
• Do not miss infectious aortitis – it requires prompt antimicrobial therapy and carries high mortality if untreated. 2

Evidence‑Based Management of Aortitis

Diagnostic Evaluation

• Obtain blood cultures and comprehensive serologic testing to rule out infectious aortitis, specifically targeting Staphylococcus aureus, Salmonella spp., Treponema pallidum (syphilis), Mycobacterium tuberculosis, and fungal pathogens. 7, 8, 9

Common Pathogens in Infectious Aortitis

• The predominant causative organisms are Staphylococcus aureus and Salmonella species; secondary pathogens include Streptococcus pneumoniae and Escherichia coli. 7, 8, 9

Management of Fungal Aortitis

• In immunocompromised patients, aortitis caused by fungi such as Candida and Aspergillus requires prompt antifungal therapy. 7, 8, 9

Indications for Surgical Intervention

• Surgical debridement, repair or replacement of the infected aortic segment, and drainage of abscesses are often necessary, especially when aneurysm formation or imminent rupture is identified. 7, 8

Cardiovascular Involvement in Ankylosing Spondylitis

• Up to 80 % of individuals with ankylosing spondylitis develop aortic root or valve disease, and nearly 50 % exhibit aortic valve regurgitation. 7, 8
• Treatment of aortic root dilation and valvular abnormalities follows standard surgical criteria applied to other aortic conditions (e.g., valve replacement when indicated). 7, 8